REGiMMUNE Establishes Broad Collaboration with RIKEN

MOUNTAIN VIEW, CA and TOKYO — Mar 22, 2007 — REGiMMUNE Corporation., a privately held biopharmaceutical company, announced today that it has enter into an Intellectual Property and Industry-Academia Collaboration Program with RIKEN, a Japanese public research institute supported by the government. This arrangement provides REGiMMUNE with a number of benefits including exclusive licenses to certain RIKEN patents.

“We are very pleased to establish this broad collaboration with RIKEN,” stated Haru Morita, President and Chief Executive Officer. “It is really encouraging for us to have such continuous support and strong commitment from RIKEN, where the original technology was developed. This closely connected relationship will boost our development competitiveness.”

About REGiMMUNE

REGiMMUNE is a biotechnology company focused on the discovery, development and commercialization of immune regulatory therapeutics to treat life-threatening and debilitating conditions, including allergies, autoimmune diseases and inflammatory disorders. The company’s proprietary technology platform, reVax (reverse vaccination), works by modulating the immune system by enhancing antigen specific immune regulatory cells. This technique is expected to be useful in conditions such as Ragweed Allergy, Rheumatoid Arthritis (RA) and Multiple Sclerosis (MS), where control of an abnormal immune response is desirable. reVax is being utilized to advance several compounds through clinical development and eventual commercialization of a broad range of products for REGiMMUNE and its partners. The company is headquartered in Tokyo, Japan and has a U.S. subsidiary in Mountain View, California.

About RIKEN

The mission of RIKEN is to conduct comprehensive research in science and technology (excluding only the humanities and social sciences) as provided for under the “RIKEN Law,” and to publicly disseminate the results of its scientific research and technological developments. RIKEN carries out high level experimental and research work in a wide range of fields, including physics, chemistry, medical science, biology, and engineering, covering the entire range from basic research to practical application. RIKEN was first organized in 1917 as a private research foundation, and reorganized in 2003 as an independent administrative institution under the Ministry of Education, Culture, Sports, Science and Technology.

US MEDIA CONTACT FOR REGiMMUNE:
Debra Bannister
530 676-8001
debra@regimmune.com